TeleDiet Study: The Impact of Dietary Education and Counseling With a Smartphone Application on Secondary Prevention of Coronary Artery Disease

TeleDiet Study: A Randomized Controlled Study Investigating the Impact of Dietary Education and Counseling With a Smartphone Application on Secondary Prevention of Coronary Artery Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05071495

Enrollment

Registered

2021-10-08

Start date

2021-03-17

Completion date

2022-08-01

Last updated

2022-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Coronary Artery Disease, Secondary Prevention, Diet Therapy

Brief summary

Digital cardiology is gaining power in the field of preventive cardiology recently, and several trials have already shown good results of dietary therapy with digital cardiology. However, there has been no reports that showed effect of dietary counseling through digital cardiology for secondary prevention of coronary artery disease. TeleDiet study investigates the impact of dietary therapy with a smartphone application on the content of meals and metabolic parameters for patients with coronary artery disease.

Interventions

DEVICESmartphone application

Smartphone application named Signal, which connects patients and health providers

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Owning a smartphone and able to use it 2. Written informed consent obtained 3. Starting cardiac rehabilitation 4. Coronary artery disease

Exclusion criteria

1. Special diet due to other reasons (eg. renal diet, pancreatic insufficiency diet) 2. Age \<18 years old 3. Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
MedDiet score (the Mediterranean diet score)	Up to 3 months	This score has the extreme values of 0 (minimum) and 55 (maximum). Higher scores mean a better outcome.

Secondary

Measure	Time frame	Description
Blood glycated hemoglobin (HbA1c) test	Up to 3 months	—
Blood creatinine (Cr) test	Up to 3 months	—
Parameters in the ergospirometer test (maximal oxygen consumption [VO2 max])	Up to 3 months	—
Parameters in the ergospirometer test (anaerobic threshold [AT])	Up to 3 months	—
Blood lipid tests (LDL-cholesterol [LDL-C], HDL-cholesterol [HDL-C], and triglyceride [TG])	Up to 3 months	—
Values of medication adherence (questionnaire of Identification of Medication Adherence Barriers [IMAB])	Up to 3 months	This scale has the extreme values of 30 (minimum) and 150 (maximum). Higher scores mean a worse outcome.
Values of quality of life (Health-related Quality of Life questionnaire [HeartQoL])	Up to 3 months	This scale has the extreme values of 0 (minimum) and 42 (maximum). Higher scores mean a better outcome.
Body weight (BW)	Up to 3 months	—
Body mass index (BMI)	Up to 3 months	Weight and height will be combined to report BMI in kg/m\^2.
Values of self-efficacy (questionnaire of General Self-Efficacy Scale [GSE])	Up to 3 months	This scale has the extreme values of 10 (minimum) and 40 (maximum). Higher scores mean a better outcome.

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026